Stock 4884 KRINGLE PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Kringle Pharma, Inc.

Equities

4884

JP3270790003

Market Closed - Japan Exchange
Other stock markets
 11:30:00 24/05/2024 am IST 		5-day change 1st Jan Change
595 JPY -2.62% Intraday chart for Kringle Pharma, Inc. +3.66% -20.88%
09/02 Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024 CI
2023 Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024
Kringle Pharma, Inc. Completes Its Pre-Ind (Investigation New Drug) Meeting with the U.S. Food and Drug Administration Regarding the Development Plan of Kp-100It, A Lyophilized Formulation of Recombinant Human Hgf, for the Potential Treatment of Acute Spinal Cord Injury
Kringle Pharma, Inc. Announces Publication of Preclinical Results from Joint Research with Keio University on Severe Spinal Cord Injury
Kringle Pharma, Inc. Announces Last Patient Out in Phase 3 Study of KP-100IT for the Treatment of Acute Spinal Cord Injury
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023
Kringle Pharma, Inc. Announces Last Patient Enrolled in Phase Iii Study for the Treatment of Acute Spinal Cord Injury
Kringle Pharma, Inc. Announces Patent Application Claims Priority for the Treatment of Chronic Spinal Cord Injury
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023
Bank of Japan's Dovish Policy Bolsters Japanese Shares; Shionogi Proceeds with Pediatric Trial of COVID-19 Vaccine
Kringle Pharma, Inc. Announces First Patient Enrollment in Phase III Clinical Study for the Treatment of Vocal Fold Scar
Kringle Pharma, Inc. Provides Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury
Kringle Pharma, Inc. Provides Consolidated Earnings Guidance for Year Ending September 30, 2023
Japan Shares Turn Red on Tokyo Inflation, Protests Over China Lockdown; Shionogi Seeks COVID-19 Vaccine Approval
Kringle Pharma, Inc. Announces Initiation of Phase III Study of HGF in Vocal Fold Scar
Kringle Pharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022
Kringle Pharma, Inc. Submits Clinical Trial Application
Kringle Pharma, Inc. Announces Jointly File A Patent Application with Keio University
Kringle Pharma, Inc. Provides Earnings Guidance for the Year Ending September 30, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4884 Stock
  4. News Kringle Pharma, Inc.
  5. Other languages